AperçuGraphiqueActualitésTraderScreen

UBS Knock-Out LLY/  DE000UM2DZL3  /

Frankfurt Zert./UBS
14/11/2024  19:40:27 Chg.-2.160 Bid20:18:04 Demandez à20:18:04 Sous-jacent Prix d'exercice Date d'expiration Type d'option
6.270EUR -25.62% 6.170
Bid taille: 5,000		 6.260
Ask la taille: 5,000		 Eli Lilly and Co 731.1378 USD 31/12/2078 Call
TeleTrader 30/10 Eli Lilly's Q3 revenue up 20% to $11.4 billion
TeleTrader 02/10 Eli Lilly to commit $4.5 billion in a new Indiana facility
Newsfile Corp 16/09 Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
TeleTrader 09/09 Eli Lilly appoints Lucas Montarce as CFO
Newsfile Corp 28/08 The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire 27/08 Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire 26/08 Eliem Therapeutics Announces Additions to its Leadership Team
GlobeNewswire 21/08 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 21/08 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 14/08 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire 14/08 Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire 08/08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08/08 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
TeleTrader 08/08 US opens higher with data, earnings in focus
GlobeNewswire 08/08 ProQR Announces Second Quarter 2024 Operating and Financial Results
TeleTrader 08/08 Eli Lilly's Q2 revenue jumps 36% to $11.3B
GlobeNewswire 08/08 Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
GlobeNewswire 07/08 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 06/08 Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire 06/08 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire 02/08 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire 01/08 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire 01/08 COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
GlobeNewswire 01/08 Compass Pathways announces second quarter 2024 financial results and business highlights
GlobeNewswire 31/07 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFC, HMNF, MORF on Behalf of Shareholders